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risk/low-risk HPV infection: clinical implications for anal cancer precursor
lesions in HIV-positive and HIV-negative MSMV. N. Pimenoff1,2, M. Félez-Sánchez1,2, S. Tous1, O. Clavero1, J. M. Godínez1,2, J. Klaustermeier1,3, M. Saunier1,2, A. Molijn4,
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(IDIBELL), 3) CIBER in Epidemiology and Public Health (CIBERESP), Barcelona, Spain, 4) DDL Diagnostic Laboratory, Rijswijk, The Netherlands and 5) Sexual
Health Clinic, Royal Perth Hospital, School of Laboratory and Pathology Medicine, University of Western Australia, Perth, AustraliaAbstractAnal condylomata are common in HIV-positive individuals and among men who have sex with men (MSM). Generally attributable to infection
by low-risk human papillomaviruses (HPVs), condylomata are considered benign low-grade squamous intraepithelial lesions (SILs). However,
anal condylomata have occasionally been linked to high-grade SIL and to oncogenic, high-risk HPVs. Here we describe the range of
intraepithelial lesions and of the associated HPVs in heterosexual men and women and MSM. Perianal and anal condylomata were
collected from 243 patients (56 heterosexual women, 61 heterosexual men and 126 MSM, including 41 HIV-positive MSM). We assessed
lesion histology and HPV genotype. Prevalence estimates and Poisson models were used. Irrespective of HIV infection status, MSM
showed a higher proportion of condylomata as high-grade SILs compared to heterosexual men/women. High-grade SILs were also more
prevalent in anal than in perianal lesions in all patient groups. HIV-positive MSM exhibited increased prevalence ratio (4.6; 95%
conﬁdence interval 2.1–10.0) of perianal low-grade SILs containing only high-risk HPVs compared to HIV-negative MSM. In addition,
more than 64% of anal SILs with a high-grade component, regardless of HIV infection, were exclusively associated with low-risk HPVs. In
anal condylomata, both high-grade and low-grade SILs can be associated with high-risk and/or low-risk HPVs. Particularly, low-grade
perianal SILs associated with high-risk HPVs were common in HIV-positive MSM, while presence of only low-risk HPVs in high-grade SILs
were common in both MSM groups. Our ﬁndings sound a note of caution for the common clinical practice for the treatment of anal
condylomata as benign lesions in MSM and HIV-positive patients.
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genera: Alpha, Beta, Gamma, Mu and NuPV. A handful of
phylogenetically related AlphaPVs are associated with 70% to
100% of cervical and anal cancer cases [1,2]. Additionally, a
global trend towards an increase in the incidence of
papillomavirus-related anal cancer has been reported [3]. TheClin Microbiol Infect 2015; 21: 605.e11–605.e19
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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into 12 carcinogenic and 15 probably or possibly carcinogenic
agents, while HPV6 and HPV11 are considered noncarcinogenic
to humans but are associated instead with proliferative,
commonly benign condyloma lesions. AlphaPVs classiﬁed as
carcinogenic are often referred to in the literature as high-risk
types, while noncarcinogenic AlphaPVs are usually referred to as
low-risk HPVs.
Anal canal intraepithelial HPV infections may progress into
histologically different types of lesions depending on the HPV
involved. Infections by low-risk HPVs, mainly HPV6 and
HPV11 (~90%), lead mostly to condyloma (condyloma acu-
minata), benign cauliﬂower-shaped genital wart lesion, while
infection by high-risk HPVs are associated with high-grade anal
intraepithelial neoplasia (AIN) [4]. However, persistent anal
infection either of low-risk or high-risk HPVs and related anal
AIN have all been associated with an increased risk for invasive
anal cancer [3–5]. In other words, AIN may be considered as
an anal cancer precursor lesion, in analogy to the cervical
intraepithelial neoplasia [3,4]. However, the precise criteria
for deﬁning precursor lesion are still wanting [6]. Earlier
studies have shown that anal condyloma, considered a variant
of grade 1 AIN [4], may also harbour foci of high-grade
dysplasia or even invasive carcinoma [6,7]. Thus, although
clinically considered as benign anal condyloma, the same lesion
might be histologically deﬁned as AIN2 or AIN3 [6]. This lack
of coherence between clinical and histopathologic diagnosis
for HPV-related anal cancer precursor lesions has led to a
recommendation of a more robust, two-tier histopathologic
classiﬁcation: low-grade anal squamous intraepithelial lesion
(LSIL) for AIN1 including condyloma, and high-grade squa-
mous intraepithelial lesion (HSIL) for AIN2 or AIN3 lesions
[6,8]. Furthermore, to follow the logic of the possible clonal
nature of warts, recently revisited as “one virus, one lesion”
[9], it has been suggested that the combination of LSIL with a
foci of HSIL reﬂects the occurrence of adjacent lesions with
separate progressive HPV infections [10]. This pattern of
mixed LSIL and HSIL lesions with multiple HPV infection is
observed especially in immunocompromised patients [6,10].
Thus, anal lesions diagnosed as condylomata are recom-
mended to be carefully examined and assessed regarding the
presence or absence of HSIL, especially when arising in
immunocompromised patients (e.g. HIV infected) or in pa-
tients otherwise considered to be at high risk, e.g. men who
have sex with men (MSM) [6].
The present cross-sectional study was designed to address
the HPV type distribution in a large Australian biopsy sample set
(n = 324) of anogenital SILs collected from nonvaccinated pa-
tients. Here we report a comprehensive HPV genotyping of one
of the largest histologically conﬁrmed case series of perianal andClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectanal SILs among heterosexual men and women, and MSM
(n = 243), including HIV-positive MSM.Materials and methodsSamples
A total of 324 formalin-ﬁxed, parafﬁn-embedded surgical anal
canal SIL samples were collected from 243 patients with known
HIV status attending the Sexual Health Clinic at Royal Perth
Hospital, Perth, Australia, between 1995 and 2011 (Fig. 1).
None of the patients in our study had been vaccinated against
HPV at the time of presentation with anogenital lesions.
Each sample was clinically identiﬁed as condyloma and
described by the operating clinician as (a) perianal if the lesion
was excised from perianal skin, or as (b) anal if the lesion was
excised from colorectal, transitional or squamous zone regarding
the dentate line of the surgical anal canal. Histology and site of
each lesion sample was further evaluated by a separate pathol-
ogist to conﬁrm the level of neoplasia in each lesion sample and
the perianal or anal origin of the lesions. This study was approved
by the ethical committee of the Royal Perth Hospital, and both
collaborating research institutes approved the study as part of a
retrospective review. Written informed consent was obtained
from each patient before sample collection.
Genotyping
Samples were processed as previously described [11]. Brieﬂy,
total DNA was obtained by proteinase K incubation. Presence
and genotyping of HPV DNA was determined using two
different detection methods, SPF10-DEiA-LiPA25 (version 1)
[12,13] and HSL-PCR/Luminex [14] systems, globally targeting
at least 68 HPV types within Alpha, Gamma, Mu and NuPV
genera. Tissue samples testing negative for the genotype assays
but that were SPF10 DNA enzyme immunoassay (DEiA) posi-
tive were further tested with three broad-papillomavirus PCR
primer sets: (a) CP4/CP5 targeting the E1 gene [15], (b) FAP59/
FAP64 targeting the L1 gene [16] and (c) GP5+GP6+ broad
spectrum, also targeting the L1 gene [17]. All the applied pro-
tocols are available in Supplementary Table S1.
Analyses
Data analysis was performed with the 243 patients data shown
in Fig. 1 using Perl (Strawberry Perl v5.14.2) and Stata (Stata-
Corp, USA). Eighty-one patients contributed both perianal and
anal samples, and data were thus analysed separately for both
anatomic sites (Fig. 1). The ﬁnal data set for both perianal and
anal analysis was stratiﬁed into groups of heterosexual men,
heterosexual women and MSM with known HIV status, i.e.
presence or absence of HIV antibodies. Given that analious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 605.e11–605.e19
FIG. 1. Schematic diagram. SIL samples used in this study. Condyloma (Condyloma acuminata), HPV X (unidentiﬁed HPV type), heterosexual women
(Women), heterosexual men (Men) and MSM. Excluded from analysis were two HIV-negative homosexual women in both perianal and anal categories,
three HIV-positive heterosexual men contributing three cases in the perianal category and one case in the anal category. For clinical diagnosis, each
sample was clinically identiﬁed as condyloma and described by the operating clinician as perianal if the lesion was excised from perianal skin and as anal
if the lesion was excised from colorectal, transitional or squamous zone regarding the dentate line of the surgical anal canal. For the histologic diagnosis,
using hematoxylin and eosin staining, the biopsy samples were further evaluated by a pathologist in relation to the epithelial types present, thus
afﬁrming the origin of the lesion as perianal if a trace of skin tissue was observed in the sample. In parallel, samples stated as anal by the operating
clinician and showing traces of glandular, squamous or anal transition zone epithelium where afﬁrmed as anal lesions. In histologic review, each sample
was further evaluated regarding the presence or absence of three-tier perianal/anal intraepithelial neoplasia (P/AIN) and as recommended [6,8] for anal
lesion diagnosis, each sample was classiﬁed as either LSIL or LSIL with foci of HSIL (L + H SIL) for further analysis.
CMI Pimenoff et al. Disagreement in intraepithelial neoplasia grade 605.e13condyloma often show foci of HSIL [6], we analysed each pa-
tient group in two categories: ﬁrstly, samples of only LSIL le-
sions and secondly, samples of LSIL combined with HSIL (Fig. 1).
HPV prevalences were compared using a two-sample test of
proportion and estimating Simpson’s diversity index. For
baseline characteristics and association analysis between HIV
status groups, an appropriate statistical method (i.e. chi-square,
Fisher’s exact and t tests) for calculating p values was used.
Prevalence ratios (PRs) among MSM were estimated using three
different Poisson regression models with robust variance.
Descriptive baseline characteristics of the patient groups are
shown in Supplementary Table S2.ResultsData
Fig. 1 summarizes the study algorithm, including clinical and
histologic diagnosis, with the following details: 179 perianal andClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infe145 anal formalin-ﬁxed, parafﬁn-embedded samples from 243
patients showed adequate DNA quality and were included in
this study. A total of 300 samples (92.6%) tested positive for the
presence of HPVs DNA using SPF10-DEIA-LiPA25 or HSL-PCR
and Luminex bead-based assays. The remaining 24 samples
(7.4%) were negative for the genotype assays but were SPF10-
DEiA HPV positive. PCR with additional broad spectrum
primer pairs [15–17] produced sequences speciﬁc for a one
particular HPV type in 17 (14 HPV6/HPV11 cases) out of these
24 samples. In seven SPF10-DEiA-positive cases, we could not
amplify any HPV DNA using the universal primers (i.e. CP4/
CP5, FAP59/FAP64, GP5+/6+) [15–17], and the samples were
further labeled as HPV X (Fig. 1).
Prevalence
Table 1 shows that LSIL with foci of HSIL were more
prevalent in anal compared to perianal lesions, irrespective
to patient group; this was also the case when excluding the
81 patient samples contributing to both anatomic sites orctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 605.e11–605.e19
TABLE 1. Anal canal HSIL-positive cases per total number of patients
Lesion
HIV negative HIV positive
Women Men MSM MSM
Perianal, n (%) Anal, n (%) Perianal, n (%) Anal, n (%) Perianal, n (%) Anal, n (%) Perianal, n (%) Anal, n (%)
All SIL lesions from all patients
LSIL 45 (97.8) 17 (70.8) 51 (98.1) 6 (50.0) 46 (90.2) 33 (47.1) 21 (84.0) 22 (61.1)
(L + H) SIL 1 (2.2) 7 (9.2) 1 (1.9) 6 (50.0) 5 (9.8) 37 (52.9) 4 (16.0) 14 (38.9)
Cases of only perianal or anal SIL in each patient
LSIL 31 (96.9) 7 (70.0) 42 (97.7) 0 12 (80.0) 15 (44.1) 4 (80.0) 11 (68.8)
(L + H) SIL 1 (3.1) 3 (30.0) 1 (2.3) 3 (100) 3 (20.0) 19 (55.9) 1 (20.0) 5 (31.2)
p-value 0.036 <0.001 0.020 1.00
Cases of both perianal and anal SIL in each patient
LSIL 14 (100) 10 (71.4) 9 (100) 6 (66.7) 34 (94.4) 18 (50.0) 17 (85.0) 11 (55.0)
(L + H) SIL 0 4 (28.6) 0 3 (33.3) 2 (5.6)a 18 (50.0)b 3 (15.0)c 9 (45.0)d
p-value 0.049 0.103 <0.001 0.041
Anal canal HSIL-positive cases per total number of patients (anatomic site ignored)
(L + H) SIL 8 (14.3) – 7 (11.5) – 40 (47.1) – 17 (41.5) –
Patients (n = 243) 56 61 85 41
p-value 0.429e 0.345f
p-value <0.001g <0.001h <0.003i
HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade anal squamous intraepithelial lesion; MSM, men who have sex with men; SIL, squamous intraepithelial lesion.
aAnal lesions from these patients also exhibited foci of HSIL.
bTotal of 16 patients among these anal cases exhibited perianal LSIL.
cOne patient exhibited foci of HSIL in both perianal and anal cases and two patients only at perianal cases.
dTotal of eight patients among these anal cases exhibited perianal LSIL.
eFishers’s exact test p value between heterosexual women and men.
fFishers’s exact test p value between HIV-negative and HIV-positive MSM.
gFishers’s exact test p value between heterosexual women and HIV-negative MSM.
hFishers’s exact test p value between heterosexual men and HIV-negative or HIV-positive MSM.
iFishers’s exact test p value between heterosexual women and HIV-positive MSM.
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anal SILs. Ignoring the anatomic site and calculating the anal
canal HSIL-positive cases per patient, HIV-negative and HIV-
positive MSM showed similar proportions of HSIL (47.1% and
41.5%, respectively, p 0.345) but a signiﬁcantly higher pro-
portion of HSILs compared to heterosexual men or women
(p-value between <0.001 and <0.003, Table 1). Heterosexual
women and men did not show signiﬁcant deviations from one
another in the ratio of LSIL to LSIL with HSIL cases within
either the perianal (45/1 vs. 51/1, p = 0.721) or anal (17/7 vs.
6/6, p = 0.195) site, between the total number of patients
with HSIL (p = 0.429, Table 1) or with baseline character-
istics (except age; Supplementary Table 2). These male and
female samples were therefore analysed together in further
analyses.
Full HPV type-speciﬁc prevalence distribution observed in
each patient group among LSILs or among all SILs is presented
in Table 2. In perianal LSILs, among HIV-positive MSM, HPV6
accounted for 12.1% of the HPV occurrences, i.e. ﬁve times
lower than the contribution of HPV6 among HIV-negative MSM
(68.7%, p = 0.015) and among heterosexual patients (78.1%, p =
0.001). This pattern was not observed in anal cases (Table 2).
Furthermore, perianal LSILs and SILs showed the broadest
richness (S) of different HPV types (19 for both categories) and
the highest diversity index (0.943 for both categories) among
HIV-positive MSM compared to any other sample group or
anatomic site (Table 2).Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectAssociations
The prevalence contribution of HPV6 single infections was
signiﬁcantly lower in HIV-positive (3.3%) compared to HIV-
negative MSM (63.0%) in perianal LSILs (p < 0.001, Table 3)
but not in anal LSILs (p = 0.785, Table 4). Poisson regression
analysis revealed the exclusive, more than ﬁve times higher
contribution of multiple HPVs infections (76.2%) for the peri-
anal LSILs among HIV-positive compared to HIV-negative MSM
(17.4%, p < 0.001, Table 3). Using only low-risk HPV-infected
cases as a reference for the Poisson regression model, the re-
sults showed signiﬁcantly different (p < 0.001) HPV type dis-
tribution in LSILs among both perianal and anal cases between
HIV-negative and HIV-positive MSM (Tables 3 and 4, respec-
tively). However, only perianal LSILs showed a signiﬁcant PR of
4.6 (95% conﬁdence interval 2.1–10.0) for high-risk HPV in-
fections without HPV6 or HPV11 (or other low-risk types)
infections for HIV-positive compared to HIV-negative MSM
(Table 3). Similarly, a signiﬁcant PR of 3.4 (95% conﬁdence in-
terval 1.5–7.9) for HPV6 or HPV11 infections with other high-
risk HPVs was observed among perianal LSILs for HIV-positive
compared to HIV-negative MSM.
Among the anal cases, more than a third—a signiﬁcantly
higher fraction of LSIL with foci of HSIL (37.8% vs. 7.1%, p =
0.041)—was exclusively associated with HPV6 single infections
in HIV-negative compared to HIV-positive MSM, respectively
(Table 4). Similarly, although not signiﬁcantly different, we
identiﬁed most anal LSIL + HSIL cases exclusively associatedious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 605.e11–605.e19
TABLE 2. Proportional prevalence of HPV types
Virus Species
Perianal Anal
HIV negative HIV positive HIV negative HIV positive
Heterosexual MSM MSM Heterosexual MSM MSM
LSIL SIL LSIL SIL LSIL SIL LSIL SIL LSIL SIL LSIL SIL
HPV6+11 (%) 91.6% 90.3% 86.3% 80.3% 32.3% 32.5% 82.6% 84.7% 83.6% 87.8% 76.3% 72.5%
HPV 6 α-10 79 (78.1) 79 (77) 35 (68.7) 38 (64.5) 5 (12.1)* 7 (15.5)
**
17 (63) 28 (69.4) 22 (58.3) 42 (51.8) 17 (59.5) 23 (45.6)
HPV 11 14 (13.5) 14 (13.3) 11 (17.6) 11 (15.8) 8 (20.2) 8 (17) 5 (19.6) 6 (15.3) 11 (25.3) 30 (36) 5 (16.8) 13 (26.9)
HPV 44 — — — — 1 (1.2) 3 (4.3) — — — — — —
HPV 74 — — 1 (1.1) 1 (1) 2 (2.5) 2 (2.1) 1 (2.2) 1 (1.4) 1 (1) 1 (0.5) — —
HPV 16 α-9 — — (1) — 5 (5.2) 3 (4.5) 5 (6.5) — 1 (1.4) — 2 (2.1) — 2 (2.1)
HPV 31 — — 1 (1.1) 1 (1) 2 (3.6) 2 (3) — — 1 (1.5) 1 (0.7) 1 (0.9) 1 (0.6)
HPV 33 — — — — 1 (2.4) 1 (2) — — — — — —
HPV 52 — — — — 2 (4.8) 2 (4) 1 (2.2) 1 (1.4) 1 (1.5) 2 (1.4) 2 (3.2) 3 (2.4)
HPV 35/52 — — — — — — 1 (4.3) 1 (2.8) — — — —
HPV 7 α-8 1 (0.5) 1 (0.5) — — 5 (9.7) 5 (8.1) — — — — 1 (0.9) 2 (1.3)
HPV 40 2 (1) 2 (1) 1 (2.2) 1 (2) 2 (2.8) 4 (5) — 1 (2.8) 1 (3) 1 (1.4) 1 (1.1) 2 (1.6)
HPV 43 — — 1 (1.1) 1 (1) 3 (4.9) 3 (4.1) — — — — 2 (3.4) 3 (4.9)
HPV 91 — — 1 (1.1) 3 (2.3) 3 (7.5) 3 (6.3) — — — — — 1 (0.5)
HPV 18 α-7 1 (0.5) 1 (0.5) 1 (0.5) 1 (0.5) 1 (1.6) 2 (3.3) 1 (2.2) 1 (1.4) — 1 (0.7) 4 (7.2) 6 (7.2)
HPV 39 — — — — 1 (1.2) 1 (1) — — — — — —
HPV 45 — — — — — — 1 (2.2) 1 (1.4) — — — 2 (1.2)
HPV 53 α-6 — — — — 3 (5.6) 3 (4.7) — — 1 (1) 1 (0.5) — 1 (0.5)
HPV 56 — — 1 (0.7) 1 (0.7) 2 (6.3) 2 (5.3) — — — — 1 (4.5) 2 (3.2)
HPV 66 1 (0.5) 1 (0.5) 1 (0.5) 1 (0.5) 2 (4) 2 (3.3) — — — 1 (0.5) — 1 (0.7)
HPV 51 α-5 1 (0.5) 1 (1) 1 (1.1) 2 (1.6) 2 (3.6) 2 (3) 2 (4.3) 2 (2.8) 2 (3.8) 3 (2.3) — —
HPV 57 α-4 1 (0.5) 1 (0.5) — — — — — — — — — —
HPV 81 α-3 1 (1) 1 (1) — — — — — — — — — —
HPV 3 α-2 — — — — — — — — 1 (0.8) 1 (0.4) — —
HPV 29 1 (0.5) 1 (0.5) — — — — — — 1 (0.8) 1 (0.4) — —
HPV 68/73 α-7/11 — — — — 1 (1.6) 1 (1.3) — — — — 1 (0.9) 1 (0.6)
HPV 1 μ — — — — — — — — — — 1 (1.5) 1 (0.9)
HPV X 3 (3.1) 3 (3.1) 2 (4.3) 2 (3.9) — — — — 1 (3) 1 (1.4) — —
S 11 11 12 13 19 19 8 10 11 14 11 16
1-D 0.418 0.418 0.592 0.661 0.943 0.943 0.638 0.564 0.682 0.66 0.756 0.823
In the case of multiple HPVs, the individual contribution of each HPV type in each single sample was proportionally calculated as 1/ni, where ni is the number of infections per
individual sample. Prevalence data are presented as n (%) unless otherwise indicated.
1-D, Simpson’s diversity index; HPV, human papillomavirus; HPV6+11, combined prevalence of HPV6 and HPV11 infection; LSIL, low-grade squamous intraepithelial lesion; S,
measure of richness; SIL, squamous intraepithelial lesion.
*Signiﬁcantly lower prevalence compared to HIV-negative MSM (68.7%, p = 0.015) or heterosexual group (78.1%, p = 0.001) within LSIL category among perianal cases.
**Signiﬁcantly lower prevalence compared to HIV-negative MSM (64.5%, p = 0.016) or heterosexual group (77.0%, p < 0.001) within all SILs among perianal cases.
CMI Pimenoff et al. Disagreement in intraepithelial neoplasia grade 605.e15with low-risk HPVs in both HIV-negative (n = 32, 86.5%) and
HIV-positive (n = 9, 64.3%) MSM (Table 4). Notably, the
observed associations did not change in replicate analyses
excluding the 81 patients that contributed to both anatomic
sites (data not shown).DiscussionAnal condyloma often presents a high proportion of multiple
HPV infections [18]. The weighted estimate approach,
commonly used in prevalence estimates of, e.g., anal and cer-
vical cancer cases [1,2], overweighs the contribution in multiple
infections of the HPV types more frequently present in single
infections while underweighting that of HPV types less
frequently present in single infections. Given the highClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infeprevalence of multiple infections in our data set, we have opted
for the proportional prevalence for each HPV type. Comparing
global HPV type distribution between studies of anogenital le-
sions is further complicated as a result of the differential
sensitivity and efﬁciency of different sampling techniques or
different genotyping methods, but also as a result of the lack of
histologic analysis of the studied sample sets [16,19]. In this
study, we report the HPV type distribution both at the level of
histologically deﬁned SILs and among any SILs.
Ignoring the anatomic site, and calculating the anal canal HSIL-
positive cases among patients, we found that irrespective of HIV
infection, MSM had signiﬁcantly more anal canal lesions with foci
of HSIL compared to heterosexual men or women. In agreement
with the seminal study by Frisch and colleagues and later reports
[20,21], we also found that anal lesions had higher proportion of
LSIL with foci of HSIL compared to perianal lesions in all patientctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 605.e11–605.e19
TABLE 3. Perianal SIL prevalence contribution and association of HPV6 single infections, HPV multiple infections, and low-risk/
high-risk HPV infections among 126 MSM.
Characteristic
LSIL (L + H) SIL
HIV negative (n [ 46) HIV positive (n [ 21) PR (95% CI) HIV negative (n [ 5) HIV positive (n [ 4) PR (95% CI)
HPV6 single infection
No 17 (37.0%) 20 (98.7%) Ref. 5 (100%) 3 (75.0%) Ref.
Yes 29 (63.0%) 1 (3.3%) 0.1 (0.0–0.6) — 1 (25.0%) 0.1 (0.0–1.3)
p, Fisher’s exact test <0.001 0.444
p, Wald test 0.011 0.077
All multiple HPV infections
No 38 (82.6%) 5 (23.8%) Ref. 1 (20.0%) 1 (25.0%) Ref.
Yes 8 (17.4%) 16 (76.2%) 4.4 (1.9–10.4) 4 (80.0%) 3 (75.0%) 6.4 (1.8–22.8)
p, Fisher’s exact test <0.001 1.000
p, Wald test <0.001 0.005
Only low-risk HPVs 40 (87.0%) 8 (38.1%) Ref. — 1 (25.0%) Ref.
Low- and high-risk HPVs 4 (8.7%) 5 (23.8%) 3.4 (1.5–7.9) 3 (60.0%) 2 (50.0%) 13.7 (0.4–447.6)
Only high-risk HPVs — 8 (38.1%) 4.6 (2.1–10.0) 2 (40.0%) 1 (25.0%) 16.7 (0.2–1638.2)
HPV X 2 (4.4%) — 0 (0) — — —
p, Fisher’s exact test <0.001 1.000
p, Wald test <0.001 0.204
PRs and 95% CIs are provided for three different robust Poisson multivariate regression models adjusted for signiﬁcant covariables. Different categorizations of HPVs infection were
used (i.e. two dichotomous variables: HPV6 single infections vs. all other HPV-infected cases; multiple infections vs. single infections and one multinomial variable with the following
categories: low-risk HPV infections; low- and high-risk HPV infections; only high-risk HPV infection; unidentiﬁed HPV X) to evaluate the associations between HPV types and HIV
status, stratifying by SIL (LSIL or L + H SIL) and site (perianal or anal). Low-risk HPV infections were used as reference group (Ref) in multinomial variable. High-risk HPV types:
HPV16, HPV18, HPV31, HPV33, HPV39, HPV45, HPV51, HPV52, HPV56, HPV68 and HPV73.
CI, conﬁdence interval; HPV, human papillomavirus; L + H SIL, low-grade squamous intraepithelial lesions with high-grade squamous intraepithelial lesions; LSIL, low-grade anal
squamous intraepithelial lesion; PR, prevalence ratio; SIL, squamous intraepithelial lesion; p, p-value.
605.e16 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIand sample categories. HPV6 and HPV11 were the most prev-
alent HPVs among perianal or anal lesion cases in each patient
and histology group (Table 2). These values are in agreement
with previous studies of anogenital lesions among HIV-negative
patients reporting HPV6 and HPV11 combined prevalence be-
tween 87% and 95% using biopsy samples or between 74% and
85% using swab samples [19,22,23]. The most intriguing ﬁnding
in our study is the observed 12.1% HPV6 prevalence among HIV-
positive MSM for perianal LSILs, which is ﬁve to six times lower
than among HIV-negative MSM (68.7%, p = 0.015), or among theTABLE 4. Anal SIL prevalence contribution and association of HPV
risk HPV infections among 126 MSM.
Characteristic
LSIL
HIV negative (n[ 33) HIV positive (n [ 22) PR (95%
HPV6 single infection
No 16 (48.5) 12 (54.5) Ref.
Yes 17 (51.5) 10 (45.5) 1.0 (0.5–
p, Fisher’s exact test 0.785
p, Wald test 0.924
All multiple HPV infections
No 26 (78.8) 14 (63.6) Ref.
Yes 7 (21.2) 8 (36.4) 1.3 (0.7–
p, Fisher’s exact test 0.429
p, Wald test <0.001
Only low-risk HPVs 27 (81.8) 15 (68.2) Ref.
Low- and high-risk HPVs 4 (12.1) 6 (27.3) 1.4 (0.8–
Only high-risk HPVs 1 (3.0) 1 (4.6) 1.4 (0.5–
HPV X 1 (3.0) — 0 (0)
p, Fisher’s exact test 0.395
p, Wald test <0.001
PRs and 95% CIs are provided for three different robust Poisson multivariate regression mode
used (i.e. two dichotomous variables: HPV6 single infections vs. all other HPV-infected cases;
categories: low-risk HPV infections; low- and high-risk HPV infections; only high-risk HPV inf
status, stratifying by SIL (LSIL or L + H SIL) and site (perianal or anal). Low-risk HPV infecti
HPV16, HPV18, HPV31, HPV33, HPV39, HPV45, HPV51, HPV52, HPV56, HPV68 and HPV7
CI, conﬁdence interval; HPV, human papillomavirus; L + H SIL, low-grade squamous intraep
squamous intraepithelial lesion; PR, prevalence ratio; SIL, squamous intraepithelial lesion; p,
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectheterosexual group (78.1%, p = 0.001). This striking difference is
exclusive to perianal lesions, as it is not observed in anal lesions.
Indeed, we identify that HIV-positive MSM with perianal LSILs
have a more than fourfold increased risk for high-risk HPV in-
fections without the presence of HPV6 or HPV11 compared to
HIV-negative MSM. This ﬁnding is in line with the proposed
cofactors enhancing anal carcinogenesis in MSM [3] but contrasts
with a study among HIV-negative patients describing higher
prevalence of oncogenic HPVs in anal compared to perianal
squamous cell carcinomas [20].6 single infections, HPV multiple infections, and low-risk/high-
L + H SIL
CI) HIV negative (n[ 37) HIV positive (n [ 14) PR (95% CI)
23 (62.2) 13 (92.9) Ref.
1.8) 14 (37.8) 1 (7.1) 0.2 (0.0–1.3)
0.041
0.090
30 (81.1) 7 (50.0) Ref.
2.4) 7 (18.9) 7 (50.0) 2.3 (1.0–5.2)
0.038
0.047
32 (86.5) 9 (64.3) Ref
2.5) 4 (10.8) 4 (28.6) 2.1 (0.8–5.4)




ls adjusted for signiﬁcant covariables. Different categorizations of HPVs infection were
multiple infections vs. single infections and one multinomial variable with the following
ection; unidentiﬁed HPV X) to evaluate the associations between HPV types and HIV
ons were used as reference group (Ref) in multinomial variable. High-risk HPV types:
3.
ithelial lesions with high-grade squamous intraepithelial lesions; LSIL, low-grade anal
p-value.
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CMI Pimenoff et al. Disagreement in intraepithelial neoplasia grade 605.e17Furthermore, a signiﬁcant fraction of LSILs with a foci of
HSIL in the anal region were exclusively associated with low-
risk HPV single infections (mainly HPV6 and HPV11) in both
HIV-status MSM groups of this study, in agreement with pre-
vious descriptions [24]. The ecologic richness of HPV types was
higher in perianal lesions among HIV-positive MSM than in any
other sample group (Table 2). The increased number of lifetime
partners among patients in the MSM groups compared to those
in the heterosexual group may have contributed at least in part
to the high HPV diversity observed among MSM
(Supplementary Table S2). The paired perianal and anal samples
from the 81 patients available in this study showed similarity in
HPV type infection pattern between perianal and anal lesions
among HIV-negative patients (n = 61, Spearman correlation
0.11, p = 0.627). However, this infection pattern between
perianal and anal lesions was signiﬁcantly different among HIV-
infected patients (n = 20, Spearman correlation 0.4, p = 0.036).
Altogether, our data indicate that the pattern of HPVs in-
fections slightly differs between anal and perianal lesions, but
mainly if the patient is also HIV infected. For clarity, none of the
samples presented in this study showed discrepancy in lesion
localization between the operating clinician and pathology re-
view (Fig. 1). However, in 11 cases (six MSM and ﬁve female
samples) clinically diagnosed as perianal by the operating clini-
cian (and referred to as perianal in this study), the histology
review did not show skin tissue; nor did it show remnants of
glandular, anal transition zone or squamous tissue. In 12 cases
(11 MSM and one female subject) clinically diagnosed as anal
disease by the operating clinician (and referred to as anal in this
study), the histology review did not show glandular, anal tran-
sition zone or squamous tissue remnants, nor traces of skin
tissue. Although the histology of these 23 samples could not be
conﬁrmed, it was also not rebutted by review. Excluding these
samples from the analysis did not change any of the signiﬁcant
results (Supplementary Tables S3 and S4).
Beyond the frequently observed AlphaPV species, we found
that the presence of HPV3 and HPV29, two AlphaPVs and HPV1,
a MuPV, were rarely reported in anal canal LSILs (Table 2).
Furthermore, we did not ﬁnd DNA from any of the targeted
GammaPVs in any SIL specimen. Most studies performed up to
date do not include GammaPVs as targets for detection, but
recent ﬁndings had suggested the presence of GammaPVs DNA
in a signiﬁcant number of condyloma samples [23] and in anal
canal of MSM [25] as well as in the male genital surface.
However, previous studies of anal canal [25] and condyloma
samples [23] used swab sampling for detecting virus DNA. This
approach is likely to sample HPV DNA present in the adjacent
tissue or present only on the surface of the lesion, which may
not necessarily be linked to the proliferation itself [26]. Thus,
on the basis of our ﬁndings on a biopsy repository, we suggestClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infethat GammaPVs may only play a marginal aetiologic role, if any,
in the development of anogenital SIL, including condyloma.
Anogenital lesions arising in a particular epithelium retain the
ancestral architecture and keratinization degree of the tissue in
which they originate, which is further modiﬁed by dysplasia
[27]. Upon infection, especially by oncogenic HPVs, different
tissues are thought to produce different epithelial immune re-
sponses [27,28]. More speciﬁcally, reduced levels of Langerhans
cells have been reported in cutaneous lesions but not in
mucosal lesions [29]. Furthermore, a previous study has re-
ported a drastic depletion of Langerhans cells and a higher rate
of dysplasia in perianal lesions compared to mucosal lesions in
HIV-infected individuals [27]. Essentially, HIV infection is
considered on the one hand to deplete the cell-mediated
Langerhans cell response to HPV infections, and on the other
hand to disrupt the epithelial tight junctions, thus enhancing
persistent HPV infection and subsequent cancer development
[30,31]. Globally, considering previous studies and our results,
we speculate that local immunodeﬁciency caused by HIV
infection may play a speciﬁc role in the development of perianal
lesions associated with oncogenic HPVs, as observed among
MSM in this study. Nevertheless, we are aware that our study
includes a limited number of HIV-infected MSM cases and also
lacks HIV-infected cases from heterosexual groups. Future
studies encompassing larger patient numbers from groups with
increased risk of anal cancer will allow researchers to discern
the possible differences in the patterns of HPVs infections in
anal lesions between HIV-positive and HIV-negative individuals.
From a clinical perspective, high-grade SIL associated with
HPV infections are considered cancer precursor lesions in the
anal canal, but the role of condylomata, i.e. low-grade SILs in
anal cancer aetiology, still remains elusive. We showed, in line
with previous studies [3,4,7], that MSM irrespective of HIV
infection had a higher proportion of anal canal high-grade SIL
lesions compared to heterosexual men or women. The most
relevant ﬁndings of this study, however, highlight that among
HIV-positive MSM, more than a third of perianal low-grade
lesions were only associated with high-risk HPVs, while more
than 64% of anal SILs with a high-grade component and irre-
spective of HIV infection were exclusively associated with low-
risk HPVs (i.e. HPV6 or HPV11). Among HIV-positive MSM, the
most evident anal cancer risk group, the increased prevalence
of low-grade perianal lesions driven only by high-risk HPVs may
have important clinical and follow-up implications. We also
remark on the concordance between the increased prevalence
of single infections by HPV6/11 in anal cancer (3%) [2]
compared to cervical cancer (<1%) [1], and the high preva-
lence in our study of anal SIL containing foci of high-grade SIL
exclusively driven by single HPV6/11 infections among HIV-
negative MSM. Altogether, our results might have signiﬁcantctious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 605.e11–605.e19
605.e18 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIadded value for the clinical treatment of anal condylomata
irrespective of HIV infection status in MSM, which are a risk
population for anal cancer, and which have not thus far been
included in the vaccination programs; nor are they expected to
receive the effects of herd immunity from current vaccination
programs. Finally, we would like to stress the importance of
careful examination and alternative treatment algorithms for
low-grade perianal lesions among MSM and among HIV-positive
heterosexual patients, especially and if focal high-grade dysplasia
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